128446-35-5
基本信息
羟丙基环糊精
2-羟丙基-倍他-环糊精
(2-羟丙基)-B-环糊精
羟丙基-Β-环糊精 100G
2-羟丙基-Β-环糊精,97%
(2-羟丙基)-BETA-环糊精
(2-羟丙基)-Β-环糊精 溶液
羟丙基-BETA-环糊精(右旋)
羟丙基-BETA-环糊精/HPBCD
HPBCD/HPCD
CAVASOL(R)W7
Cavasol? W7 HP
2-Hydroxypropyl-&beta
Hydroxypropyl-b-Cyclodextrin
beta-hydroxypropylcyclodextrin
(2-Hydroxypropyl)-beta-cyclode
Hydroxypropyl Betadex (200 mg)
2-Hydroxypropyl-B-Cyclodextrin
物理化学性质
| 熔点 | 278 °C (dec.) |
| 沸点 | 400℃ |
| 密度 | 1.05 at 20.3℃ |
| 折射率 | 125 ° (C=1, H2O) |
| 储存条件 | 2-8°C |
| 溶解度 | H2O: 45 % (w/v) |
| 形态 | solution (clear, colorless) |
| 颜色 | 白色至微黄色 |
| 旋光性 (optical activity) | [α]26/D +139°, c = 1 in H2O |
| 水溶解性 | 易溶于水。 |
| InChIKey | ODLHGICHYURWBS-FOSILIAISA-N |
| LogP | -4 at 20℃ |
| 表面张力 | 63.6-65mN/m at 1g/L and 22℃ |
| EPA化学物质信息 | .beta.-Cyclodextrin, 2-hydroxypropyl ethers (128446-35-5) |
安全数据
| 危险性符号(GHS) |  GHS07 |
| 警示词 | 警告 |
| 危险性描述 | H315-H319-H335 |
| 防范说明 | P280-P261 |
| 安全说明 | 24/25 |
| WGK Germany | 3 |
| RTECS号 | GU2293332 |
| TSCA | Yes |
| 海关编码 | 29400090 |
| 毒性 | mouse,LD,intravenous,> 5gm/kg (5000mg/kg),Journal of Pharmaceutical Sciences. Vol. 84, Pg. 1223, 1995. |
常见问题列表
羟丙基-BETA-环糊精是目前研究最为深入，应用最广泛的环糊精衍生物之一。其主要应用于食品、医药、化妆品行业。
羟丙基-β-环糊精(HBC)是一种应用广泛的改性环糊精，由7个葡萄糖单位形成亲脂腔。药物与羟丙基-β-环糊精络合后，水溶性会大大增强。2-羟丙基的数目在5到14之间。
羟丙基-BETA-环糊精是一种理想的注射剂增溶剂和药物赋形剂，可以提高难溶性药物的水溶性，增加药物稳定性、提高药物生物利用度，使药剂的疗效增加或服用量减少，可以调整或控制药物的释放速度，降低药物毒副作用。
1、在食品、香料领域，可提高营养分子的稳定性和长效性，可掩盖或矫正食品营养分子的不良气味和口味，可改进生产工艺和产品品质。该产品在水中的溶解度很好，取代度4及以上可以和水任意比例混溶，在50%的乙醇和甲醇中也能溶解。
2、在化妆品原料中用作稳定剂、乳化剂、去味剂等，可降低化妆品中有机分子对皮肤粘膜组织的刺激，增强有效成分的稳定性，防止营养成分的挥发、氧化。它有一定的相对吸湿性。
3、在医药工业中，由于相对表面活性和溶血活性比较低且对肌肉没有刺激性，所以它是一种理想的注射剂增溶剂和药物赋形剂。
| Target | Value |
|
amyloid-β aggregation
() |
Cell treatment with (2-Hydroxypropyl)-β-cyclodextrin results in the activation of the transcription factor EB, a master regulator of lysosomal function and autophagy, and in enhancement of the cellular autophagic clearance capacity. (2-Hydroxypropyl)-β-cyclodextrin treatment reduces intracellular cholesterol resulting in significant leukemic cell growth inhibition through G2/M cell-cycle arrest and apoptosis. The IC 50 values for (2-Hydroxypropyl)-β-cyclodextrin after 72 hours exposure are in the range of 3.86–10.09 mM. (2-Hydroxypropyl)-β-cyclodextrin also shows anticancer effects against CML cells expressing a T315I BCR-ABL mutation (that confers resistance to most ABL tyrosine kinase inhibitors), and hypoxia-adapted CML cells that have characteristics of leukemic stem cells. In addition, colony forming ability of human primary AML and CML cells is inhibited by (2-Hydroxypropyl)-β-cyclodextrin.
(2-Hydroxypropyl)-β-cyclodextrin administration promotes transcription factor EB-mediated clearance of proteolipid aggregates that accumulate due to inefficient activity of the lysosome-autophagy system in cells derived from a patient with a lysosomal storage disorder. Intraperitoneal injection of (2-Hydroxypropyl)-β-cyclodextrin significantly improves survival in leukemia mouse models. Systemic administration of (2-Hydroxypropyl)-β-cyclodextrin to mice has no significant adverse effects.